Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
about
Interventions for helping people recognise early signs of recurrence in depressionMeta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressantsIdentifying moderators of the adherence-outcome relation in cognitive therapy for depression.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.Therapist competence in cognitive therapy for depression: predicting subsequent symptom change.Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Follow up of patients who start treatment with antidepressants: treatment satisfaction, treatment compliance, efficacy and safetyPartial remission, residual symptoms, and relapse in depression.RETRACTED: Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial.Gains in employment status following antidepressant medication or cognitive therapy for depression.Pharmacotherapy to sustain the fully remitted state.Clinical studies on the efficacy of agomelatine on depressive symptoms.Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective studySpecific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression.Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS)Continuation and maintenance therapy of early-onset major depressive disorder.Safety and adverse event profile of duloxetine.Report by the ACNP Task Force on response and remission in major depressive disorder.Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.In cognitive therapy for depression, early focus on maladaptive beliefs may be especially efficacious for patients with personality disordersAssessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) studyCognitive Therapy Skills Predict Cognitive Reactivity to Sad Mood Following Cognitive Therapy for Depression.A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.Meta-analysis of relapse prevention antidepressant trials in depressive disorders.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.When to stop?Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy.Continuation and maintenance use of antidepressants in recurrent depression.Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries.Guidelines in major depressive disorder, and their limitations.
P2860
Q24247096-4BF902A3-333D-4668-B767-7EADDFBE1D35Q24624760-B11CC20B-DE45-4134-8B1A-9BDADC3BFEC5Q27334150-63F6C800-1DFB-4017-829D-468BC688CE20Q31121208-3C3715E1-D010-431C-81A6-15A92043478BQ31161297-1A021B46-9DAD-4562-9AEE-68DB11EDFE42Q33667966-80B96CB6-EC38-4169-85B9-029A2A9248D0Q33886704-1EFA12D5-DCB1-4796-83F6-FAFBE0FBB07EQ33894374-BBB0708B-A7C4-4898-8710-3F138807BC6CQ33950999-D835445E-3B50-486B-9881-E7EE69D757C1Q33959019-396B1A75-E2D2-49C5-9C75-38D398F7C468Q34578945-F0339535-5852-426B-A031-17FB14B48B3EQ34590507-FB2F4AF6-7FC8-46CA-891C-8811B5F71770Q34593362-9CA7B638-985E-46AF-B58B-6E94E09008B7Q34603620-85A9E7FB-1BE9-4767-82C7-DB6977A7BDA0Q34664030-057B056B-997F-43CE-8F6C-140F0F422561Q34691663-D865ED42-8416-4D12-87DC-DEF88377D36BQ34783161-AF441BB6-7770-4423-8E9A-D33037B0A99EQ34999604-4AE3372A-BD1C-4F2B-ABA1-01BEA2AA796CQ35098031-F5A6A8E9-370C-4564-840D-55F12B7B4867Q35746646-59E3CFB6-09A7-4E7E-B2C0-400F2F77A515Q35853949-5A2C9DE6-D342-4D9E-BDD0-236B7A59A543Q35862776-B4E977E1-A039-467B-8E4A-0CAF1B5EE21BQ35967580-983EF6A6-847A-4B04-8732-F4D89217F8AEQ36082786-2541E60D-711B-432C-894C-A7CDAF68B4E3Q36118719-78818D68-A828-4504-BC06-EC693B08CDE8Q36238434-AC3AC25C-5097-4B84-9FBA-000FEC0DD0C4Q36299961-6B661402-FDED-45A9-878A-DE324207AEB2Q36516394-50087C39-F316-45DB-A591-BDF1F6FBAC8DQ37014627-0F839E16-A5ED-4330-ACED-9F0844D76D59Q37073590-BD0DED93-3106-4957-BE4F-7251214F2ECEQ37250338-2D540B56-85F8-4C78-B88D-515751FDCAE7Q37401131-0F9F045C-B0B1-4862-9784-8F7773D611B3Q37651165-734CF2E7-C668-4D5F-B919-B7A3280B6868Q37773366-FBE99F71-D164-44D0-86D1-95891C43C72FQ38476909-1D293A01-AA77-49ED-B77B-595A313428ABQ42993505-770A4423-CC34-4D56-8D5C-6EDEF56B7B83Q43289055-19FF7336-DC9E-4DA7-A31A-3780DA3EE1A9Q46845071-82A24E4A-B43C-4C27-BDAD-2572EF41AEF6Q49384717-F0504FA8-AF26-4AA8-B0B2-5720CE5F8156Q51922807-E1E16D3A-F334-4BDB-B38E-2C1CE056AB2F
P2860
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Optimal length of continuation ...... ong-term fluoxetine treatment.
@en
Optimal length of continuation ...... ong-term fluoxetine treatment.
@nl
type
label
Optimal length of continuation ...... ong-term fluoxetine treatment.
@en
Optimal length of continuation ...... ong-term fluoxetine treatment.
@nl
prefLabel
Optimal length of continuation ...... ong-term fluoxetine treatment.
@en
Optimal length of continuation ...... ong-term fluoxetine treatment.
@nl
P2093
P356
P1476
Optimal length of continuation ...... ong-term fluoxetine treatment.
@en
P2093
Amsterdam JD
Beasley CM Jr
Michelson D
Quitkin FM
Reimherr FW
Rosenbaum JF
P304
P356
10.1176/AJP.155.9.1247
P407
P577
1998-09-01T00:00:00Z